| Xiaoying Quan. A case of sorafenib-induced severe thrombocytopenia during treatment of unresectable hepatocellular carcinoma. Oncol Transl Med, 2021, 7: 235-238. |
| 索拉非尼治疗不可切除肝癌致极重度血小板减少1例 |
| A case of sorafenib-induced severe thrombocytopenia during treatment of unresectable hepatocellular carcinoma |
| Received:April 18, 2021 Revised:October 22, 2021 |
| DOI：10.1007/s10330-021-0492-2 |
| 中文关键词: 血小板减少；索拉非尼；肝癌 |
| 英文关键词: thrombocytopenia; sorafenib; hepatocellular carcinoma |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Xiaoying Quan* | The Sixth People''s Hospital of Chengdu | 1193084163@qq.com |
|
| Hits: 5549 |
| Download times: 6241 |
| 中文摘要: |
| 1例81岁男性肝癌患者行TACE联合索拉非尼治疗，TACE治疗前后血小板正常，口服索拉非尼400mg po bid治疗，期间患者腹泻明显，遂减量为200mg po bid继续治疗。后患者出现牙龈出血并进行性加重，血常规提示PLT 2*10^9/L。诊断极重度血小板减少，停用索拉非尼，予以止血、输血小板、输红悬、对症治疗好转后出院。随访至今，患者未再发生出血。 |
| 英文摘要: |
| An 81-year-old male with unresectable hepatocellular carcinoma underwent transarterial chemoembolization
(TACE) combined with sorafenib. Platelet count was normal before and after TACE treatment, after which
oral administration of sorafenib (400 mg po bid) was initiated. During this period, the patient experienced
significant diarrhea, so the dosage was reduced to 200 mg po bid. Later, the patient showed obvious
gingival bleeding with progressive exacerbation, and his blood routine examination showed a platelet count
of 2 × 109 cells/L. The patient was clinically diagnosed with extreme severe thrombocytopenia. The patient
was advised to stop taking sorafenib and was immediately treated with hemostasis, platelet transfusion,
and suspended red blood cells. After the above treatment, the patient’s symptoms improved, and he was
discharged. Up to the date of follow-up, there was no further bleeding. |
|
View Full Text
Download reader HTML全文 |
| Close |